What does this biotech insider know that the rest of us don't? Print
By Michael Morhamus   
Tuesday, 13 September 2011 04:04
FDA calendar It has already been noted that the insider buying at some biotech firms has been very active in these markets, but the actions of one insider in particular have caught my attention. His spending has been off the charts the past few weeks and in particular his apetite for shares of Seattle Genetics (Nasdaq:SGEN); the firm engaged in development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases.

SGEN was founded in 1998 by Clay B. Siegall- who as CEO sold shares for as much as $20.66 per share in July.

On the other hand, Felix Baker, a Director and already a 10+% owner in SGENhas been buying shares aggressively since mid-August, putting in big buys worth $275,723 $17,925,663  $2,206,641 and  $30,285 respectively under various entities registered to him.

We know that Seattle Genetics plans to charge $13,500 per dose of ADCETRISTM, the company's Hodgkin lymphoma medicine- but therein lies the problem. Investors started dropping shares fearing that the company would follow cancer drugs like Dendreon Corp.'s Provenge in disappointing early sales.

ADCETRISTM became the first approved oncology treatment for the disease in three decades after the U.S. Food and Drug Administration granted accelerated approval of ADCETRISTM for two indications: (1) the treatment of patients with Hodgkin lymphoma and (2) the treatment of patients with systemic anaplastic large cell lymphoma (ALCL) after failure of at least one prior multi-agent chemotherapy regimen.

When the drug was tested patients were given, ADCETRISTM in eight infusions every three weeks. Given the announced price tag, that would end up costing a patient a total of $108,000 per course of treatment.

"There is a general concern about owning any company into a drug launch, and the recent blowup of Dendreon does not help," Jason Kantor, an analyst with RBC Capital Markets told a San Francisco newspaper. "General concerns relate to reimbursement, uptake, execution and expectations."

"Dendreon has a drug for prostate cancer that serves millions of American males," he said. "Seattle Genetics has a niche oncology product for a much smaller market."

Browsing through the BioMedReports Trade Catalyst and FDA Calendar, I see four upcoming milestones listed for the company, but none as big as the planned 4th quarter launch of ADCETRIS in the U.S. and abroad.

Seattle Genetics has U.S. and Canadian commercialization rights and the Takeda Group has rights to commercialize ADCETRIS in the rest of the world. Seattle Genetics and the Takeda Group are funding joint development costs for ADCETRIS on a 50:50 basis, except in Japan where the Takeda Group will be solely responsible for development costs.

Interestingly, as the markets have been trading sideways and investors have been more cautious, Baker has also been doing even more heavy buying as an insider at two other firms:

First, Pharmacyclics Inc. (NASDAQ:PCYC), the biopharmaceutical company focused on designing, developing and commercializing therapies whose pipeline includes a treatment for chronic inflammatory diseases like rheumatoid arthritis and lupus; a the treatment of pancreatic cancer and gastric/colon cancer; and a treatment of relapsed and refractory lymphoma and solid tumors, among others. Interestingly, BioMed Report’s FDA Calendar shows more than a handful of catalysts, mostly related to clinical study milestones that appear to indicate that PCYC’s clinical programs are all pushing ahead with plenty of momentum.

Second, he's been buying lots of ViroPharma (NASDAQ:VPHM) whose core focus is on providing patients and physicians new therapeutic alternatives for great unmet medical needs and whose product folio includes: Vancocin® Capsules for treatment of antibiotic-associated pseudomembranous colitis; Cinryze® (C1 Esterase Inhibitor (human)) for routine prophylaxis against angioedema attacks in adolescent and adult patients with Hereditary Angioedema (HAE) and others. ViroPharma has collaborations with Halozyme Therapeutics Inc., Biotest AG, MicroDose Technologies, Inc, Lev Pharmaceuticals, Inc., GlaxoSmithKline, Wyeth, Eli Lilly and Company, Medidata Solutions, Norwich Pharmaceuticals Inc., etc. The BioMedReports’ FDA Calendar shows one upcoming catalyst for the firm as they anticipate initiating a Phase III study in the later part of 2011.

On Monday, Seth Jayson of MotleyFool warned loudly that ViroPharma might burn investors, stating: "Investors should watch the top line carefully during the next quarter or two. For the last fully reported fiscal quarter, ViroPharma's year-over-year revenue grew 18.2%, and its AR grew 41.8%. That's a yellow flag."

It will be interesting to see who was right about buying at these price levels. The reporter and the shareholders or the insider.

Disclosure: None

Michael Morhamus is a contributor at Seeking Alpha. You can follow him there as he covers stocks both in and out of the healthcare sector.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus